Clinical Trial of HIV Vaccine Combinations in Healthy Men and Women

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 6, 2017

Primary Completion Date

February 10, 2020

Study Completion Date

February 10, 2020

Conditions

Human Immunodeficiency Virus

Interventions

BIOLOGICAL

Ad4-EnvCN54

Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54

BIOLOGICAL

MVA-CN54

Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54

BIOLOGICAL

CN54gp140/MPLA

Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant

Trial Locations (1)

NIHR Imperial Clinical Research Facility, London

All Listed Sponsors

lead

Imperial College London

OTHER

NCT03408262 - Clinical Trial of HIV Vaccine Combinations in Healthy Men and Women | Biotech Hunter | Biotech Hunter